Company news

Shanghai Shyndec Pharmaceutical Co., Ltd. news in 2025

Shanghai Shyndec Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Announcement on Resolutions of the 1st Meeting of the 9th Board of Directors

December 24, 2025

Notice on Convening the 3rd Extraordinary General Meeting in 2025

December 8, 2025

Announcement on Election of Employee Director

November 21, 2025

Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025

November 5, 2025

Announcement on Progress in Public Listing and Transfer of Equity in a Holding Subsidiary and Completing Industrial and Commercial Change

October 31, 2025

Report for Q3 2025

October 29, 2025

Announcement on Prospective Winning of the 11th National Centralized Drug Procurement

October 28, 2025

Announcement on the Progress and Transaction Results of the Public Listing Transfer of Subsidiary Equity

October 17, 2025

Announcement on Wholly-owned Subsidiary Obtaining Approval for Marketing of Chemical APIs

October 10, 2025

Announcement on Resignation of Senior Management Members

October 9, 2025

Announcement on Resolutions of the 24th (Extraordinary) Meeting of the 8th Board of Directors

September 22, 2025

Announcement on the Voluntary Information Disclosure of Drug Passing the Consistency Evaluation for Generic Drugs

September 17, 2025

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

September 15, 2025

Announcement on the Wholly-owned Subsidiary Obtaining the Approval Notice for Drug Supplementary Application

September 12, 2025

Announcement on Implementation of Semi-annual Dividend Distribution for 2025

September 8, 2025

Notice on Convening the 2nd Extraordinary General Meeting in 2025

August 29, 2025

Announcement on Progress in Public Listing and Transfer of Equity of Holding Subsidiary

August 28, 2025

Announcement on Resignation of Senior Management Member

August 3, 2025

Brief Announcement on Semi-annual Earnings for 2025

July 17, 2025

Announcement on Implementation of Dividend Distribution for 2024

July 9, 2025

Indicative Announcement on the Proposed Pre-Listing for Public Transfer of Equity Interests in a Controlling Subsidiary

June 30, 2025

Announcement on Wholly-owned Subsidiary Obtaining Notice of Approval for Marketing Application of Chemical APIs

June 27, 2025

Announcement on Resolutions of the 2024 Annual General Meeting

June 26, 2025

Announcement on the Voluntary Information Disclosure of the Holding Subsidiary's Drug Passing the Consistency Evaluation for Generic Drugs

June 20, 2025

Announcement on Progress in Accepting Drug Marketing Authorization by Holding Subsidiary

June 10, 2025

Announcement on Resolution of the 22nd Meeting of the 8th Board of Directors

June 5, 2025

Announcement on the Holding Subsidiary Obtaining the Approval Notice for Drug Supplementary Application

May 28, 2025

Announcement on Attending Collective Annual Report Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025

May 8, 2025

Report for Q1 2025

April 28, 2025